NCT03994601 2026-01-20
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
Clinical Trials
48 trialsNCT02743494 2025-11-18
CheckMate 577
Bristol-Myers Squibb
Phase 3 Completed
NCT05025085 2025-10-15
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
Agenus Inc.
Phase 1 Completed
NCT03900442 2025-09-02
Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort
Prescient Therapeutics, Ltd.
Phase 1 Completed
NCT04467593 2025-08-05
MATTERS
ElmediX
Phase NA Completed
NCT03459222 2025-04-02
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03352531 2025-02-28
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
Akeso
Phase 1 Completed
NCT01394016 2024-09-19
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT04335253 2024-09-19
First-In-Human Study of EOS884448 in Participants with Advanced Cancers.
iTeos Therapeutics
Phase 1 Completed
NCT00610194 2023-10-18
Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients
Bayer
Phase 1 Completed
NCT00658671 2023-02-06
A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
CASI Pharmaceuticals, Inc.
Phase 1 Completed
NCT02996110 2022-12-19
FRACTION-RCC
Bristol-Myers Squibb
Phase 2 Completed
NCT03312842 2022-05-26
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Completed
NCT03203876 2022-03-10
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03792750 2022-02-28
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03475251 2022-02-18
A Study of CS1003 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Completed
NCT00687505 2021-12-13
Safety Study of FP-1039 To Treat Cancer
Five Prime Therapeutics, Inc.
Phase 1 Completed
NCT02407990 2021-11-17
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
BeiGene
Phase 1 Completed
NCT03661632 2021-11-08
An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03745807 2021-10-04
An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT04071262 2021-09-21
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00085787 2020-10-14
A Study of ARRY-142886 in Patients With Advanced Cancer
Array BioPharma
Phase 1 Completed
NCT00710736 2020-10-06
A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer
Array BioPharma
Phase 1 Completed
NCT00833326 2020-10-06
A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer
Array BioPharma
Phase 1 Completed
NCT00881569 2020-09-28
Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017
Daiichi Sankyo
Phase 1 Completed
NCT01393990 2020-03-24
A Study of LY2228820 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02383212 2020-01-27
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Regeneron Pharmaceuticals
Phase 1 Completed
NCT01583777 2020-01-03
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
Acrotech Biopharma Inc.
Phase 1 Completed
NCT04193319 2019-12-10
Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT01863485 2019-07-05
Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China
AnewPharma
Phase 1 Completed
NCT02642016 2019-06-12
A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
Celldex Therapeutics
Phase 1 Completed
NCT02825563 2019-05-22
A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT03192943 2019-04-01
A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT01287520 2019-02-25
A Study of LY2090314 in Patients With Advanced or Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01296568 2019-01-07
C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT02245204 2018-11-21
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
Phase 1 Completed
NCT01576406 2018-10-25
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
Pfizer
Phase 1 Completed
NCT02014909 2017-07-24
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Celldex Therapeutics
Phase 1 Completed
NCT01287546 2017-02-15
A Study of LY2875358 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01976143 2016-12-22
A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety
Nektar Therapeutics
Phase 1 Completed
NCT00785226 2016-10-17
RDEA119 and Sorafenib Combination Dose Escalation Study
Bayer
Phase 1/2 Completed
NCT00698841 2015-12-24
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT00907738 2015-05-21
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00518739 2015-03-27
MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01423903 2014-01-15
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 1 Completed
NCT00656461 2009-11-25
Phase 1 Study of MKC-1 in Patients With Advanced Cancer
CASI Pharmaceuticals, Inc.
Phase 1 Completed
NCT00421135 2009-09-17
A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer
Alaunos Therapeutics
Phase 1 Completed
NCT00664170 2009-05-28
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Mast Therapeutics, Inc.
Phase 1 Completed